What type of drug is ustekinumab?

Ustekinumab (Ustekinumab) is a humanized monoclonal antibody and a biological agent. It targets two key inflammatory mediators, interleukin-12 (IL-12) and interleukin-23 (IL-23), and inhibits their binding to receptors, thereby effectively regulating abnormal responses of the immune system. Because IL-12 and IL-23 play important roles in the inflammatory process of many autoimmune diseases, ustekinumab reduces inflammation and disease symptoms by blocking these signaling pathways.

Ustekinumab is mainly used to treat a variety of moderate to severe autoimmune diseases, especially in the field of dermatology and inflammatory diseases. Its broadest indications include moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn's disease. By modulating the immune system, ustekinumab can effectively alleviate the symptoms of these diseases, reduce inflammatory responses, and improve patients' quality of life.

As a biologic, ustekinumab is usually administered as a subcutaneous injection, with the frequency of administration varying depending on the type of disease and stage of treatment. Compared with traditional immunosuppressants, ustekinumab is more targeted and has relatively fewer side effects, but potential infection risks and immune-related adverse reactions still need to be closely monitored during use.

Generally speaking, ustekinumab is a targeted biological drug targeting specific immune pathways and is suitable for the treatment of a variety of autoimmune inflammatory diseases. It helps patients control disease progression by precisely regulating the immune system and is one of the important drugs in the field of modern immunotherapy.

Reference materials:https://www.drugs.com/donanemab.html